CAEL-101
astrazeneca
[]
#eha2023 | michaela liedtke shares 18-mo safety and tolerability data from the phase 2 study of cael-101 in combination with soc anti-pcd therapy, for the treatment of al amyloidosis. 60% had teaes grade 3, 52% had saes. 23% cardiac-evaluable pts responders. #amyloidosis 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma